Foresee Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Foresee Pharmaceuticals şirketinin toplam hissedar öz sermayesi NT$1.0B ve toplam borcu NT$200.0M olup, bu da borç-öz sermaye oranını 20% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla NT$1.6B ve NT$593.1M dir.

Anahtar bilgiler

20.0%

Borç/özkaynak oranı

NT$200.00m

Borç

Faiz karşılama oranı	n/a
Nakit	NT$972.76m
Eşitlik	NT$1.00b
Toplam yükümlülükler	NT$593.11m
Toplam varlıklar	NT$1.59b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

We Might See A Profit From Foresee Pharmaceuticals Co., Ltd. (GTSM:6576) Soon

Mar 24

Investors Who Bought Foresee Pharmaceuticals (GTSM:6576) Shares A Year Ago Are Now Up 41%

Dec 22

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 6576 'nin kısa vadeli varlıkları ( NT$1.3B ) kısa vadeli yükümlülüklerini ( NT$500.4M ) aşıyor.

Uzun Vadeli Yükümlülükler: 6576 şirketinin kısa vadeli varlıkları ( NT$1.3B ) uzun vadeli yükümlülüklerini ( NT$92.7M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 6576 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 6576 şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 20% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 6576 şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: 6576 serbest nakit akışı her yıl % 2.6 1 yıl yetecek nakit akışına sahip olacaktır.

Foresee Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Foresee Pharmaceuticals Co., Ltd. Announces Submission of the NDA to the U.S. FDA for the 3-month Version of CAMCEVI for the Treatment of Advanced Prostate Cancer

Foresee Pharmaceuticals Co., Ltd. Announces on Behalf of Subsidiary, Foresee Pharmaceuticals Australia Pty Ltd, the Preliminary Results from the Linvemastat (Fp-020) Phase 1 Trial

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Foresee Pharmaceuticals Co., Ltd. Announces Several New Developments Related to its SIF Long-Acting Injectable (LAI) Technologies - Solidifying its Position as a Leader in Complex Long-Acting Injectability Products

Foresee Pharmaceuticals Co., Ltd. to Report Q2, 2024 Results on Aug 14, 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Foresee Pharmaceuticals Announces First Subject Dosed in Its First-In-Human Clinical Trial of FP-020

Foresee Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on May 03, 2024

Foresee Pharmaceuticals Receives Positive Recommendation from Data and Safety Monitoring Board to Continue the Casppian Study

Full year 2023 earnings: EPS misses analyst expectations

Foresee Pharmaceuticals Co., Ltd. has filed a Follow-on Equity Offering.

Consensus revenue estimates fall by 38%

Foresee Pharmaceuticals Co., Ltd. Announces Last Patient Enrolled in the China Registration Clinical Trial of Leuprolide Injectable Emulsion in Prostate Cancer Has Completed Treatment

Foresee Pharmaceuticals Co., Ltd. Submits Phase 3 IND (Investigational New Drug) Application to China NMPA

Foresee Pharmaceuticals Announces First Patient Dosed in the Casppian, Phase 3 Clinical Trial of Leuprolide (FP-001) Injectable Emulsion, 42 mg for the Treatment of Central Precocious Puberty Patients

Foresee Pharmaceuticals to Present Phase 1/2 Fanconi Anemia Clinical Study Design for its ALDH2 Activator FP-045 at the Fanconi Anemia Research Fund 2023 Scientific Symposium

New minor risk - Shareholder dilution

Foresee Pharmaceuticals Announces FDA Orange Book Listing of New U.S. Patent for Camcevi®, Extending Patent Protection to 2039

New minor risk - Revenue size

Second quarter 2023 earnings: Revenues miss analyst expectations

Forecast to breakeven in 2024

Price target decreased by 12% to NT$122

No longer forecast to breakeven

Foresee Pharmaceuticals Co., Ltd. Announces Appointment of Ben Liu as Independent Director

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Foresee Pharmaceuticals Co., Ltd. Receives Approval from China NMPA for the Application of Phase 3 IND for FP-001 42 mg in Patients with Central Precocious Puberty

Foresee Pharmaceuticals Co., Ltd. Receives Approval from Taiwan FDA for the Application of Phase 3 IND for FP-001 42 Mgin Patients with Central Precocious Puberty

Foresee Pharmaceuticals Co., Ltd. Announces the Submission of A Phase 3 Clinical Trial Application for FP-001 42 Mg in Patients with Central Precocious Puberty to EMA

Less than half of directors are independent

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Foresee Pharmaceuticals Co., Ltd. Announces Phase 3 Clinical Trial Application for Fp-00142 Mg in Patients with Central Precocious Puberty Has Been Accepted by China NMPA for Substantial Review

Consensus revenue estimates fall by 32%

Foresee Pharmaceuticals Co., Ltd. Proceeds with FP-001 42 Mg Phase 3 Clinical Trial in Patients with Central Precocious Puberty

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Foresee Pharmaceuticals Co., Ltd. Submits IND for FP-045 in Patientswith Fanconi Anemia by TRPharm to the Ministry of Health of Turkey

Foresee Announces Phase 2 Results of FP-025 Inpatients with Covid-19 Associated ARDS

Forecast to breakeven in 2024

Foresee Pharmaceuticals Announces European Commission Approval of CAMCEVI® for the Treatment of Advanced Prostate Cancer

First quarter 2022 earnings released: NT$1.04 loss per share (vs NT$1.36 loss in 1Q 2021)

Foresee Pharmaceuticals Co., Ltd. Approves Appointment of Max Chan as Corporate Governance Officer

Israel Accepts for Substantial Review of Marketing Authorization Application for CAMCEVI 42 mg of Foresee Pharmaceuticals Co., Ltd

Price target increased to NT$130

Less than half of directors are independent

Accord BioPharma in Partnership with Foresee Pharmaceuticals Co., Ltd., the U.S. Launch of CAMCEVI (Leuprolide) 42Mg Injection Emulsion for the Treatment of Advanced Prostate Cancer in Adults

Full year 2021 earnings: EPS exceeds analyst expectations

No longer forecast to breakeven

Price target increased to NT$130

Consensus forecasts updated

Foresee Pharmaceuticals Co., Ltd. Announces Registration Clinical Trial Application for CAMCEVI42 Mg Accepted by China NMPA for Substantial Review

Foresee Pharmaceuticals Co., Ltd. Announces Positive Recommendation from Second IDMC Review Meeting to Continue FP-025 Covid-19/ARDS Phase 2/3 Study

Tolmar Files Complaint Against Foresee Pharmaceuticals Co., Ltd. for Patent Infringement

Foresee Announces Positive Recommendation from IDMCPhase 2 Safety Review Meeting to Continue FP-02 Covid-19/ARDS Phase 2/3 Study Without Change

Price target increased to NT$125

Foresee Pharmaceuticals Co., Ltd. Announces FDA Approval of CAMCEVI 42 mg for the Treatment of Advanced Prostate Cancer

Price target decreased to NT$112

First quarter 2021 earnings released: NT$1.36 loss per share (vs NT$1.10 loss in 1Q 2020)

Senior Director & Head of QA has left the company

We Might See A Profit From Foresee Pharmaceuticals Co., Ltd. (GTSM:6576) Soon

New 90-day high: NT$107

Foresee Pharmaceuticals Enters Exclusive License Agreement with Intas Pharmaceuticals for Commercialization in the United States

Foresee Received Notification from US FDA That Itmay Proceed with the FP-025 Phase 2/3 Clinical Trials Inpatients with COVID-19 Associated ARDS

Price target lowered to NT$123

Foresee Pharmaceuticals Co., Ltd. announced that it has received TWD 90 million in funding

Foresee Pharmaceuticals Co., Ltd. has completed a Follow-on Equity Offering in the amount of TWD 1.32 billion.

Investors Who Bought Foresee Pharmaceuticals (GTSM:6576) Shares A Year Ago Are Now Up 41%

Foresee Pharmaceuticals Enters Into Exclusive License Agreement with GenScience Pharmaceuticals for the Commercialization of Camcevi(TM) in China

New 90-day high: NT$102

Earnings miss expectations

Foresee Pharmaceuticals Co., Ltd. Announces New Drug Application for FP-001 LMIS 50mg Accepted for Review by the U.S. Food and Drug Administration

Analysts lower revenue estimates to NT$143.0m

First half earnings released

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi